Mr. Guolin Wang, Director and Secretary of the Board of Medicilon, won another award!

Recently, the selection of 2021 elite board secretaries of the Cai Lian She (CLS) and the Night of Qingdao Board Secretaries were held in Haitian Center Complex, Qingdao.  There are more than one hundred listed company secretaries attended the ceremony.  Mr. Wang, the Director and Secretary of the Board of Shanghai Medicilon Inc. (stock code: 688202.SH) (Medicilon), won the “Elite Board Secretary Award”.

Elite Award

The selection of elite board secretaries is a commendation activity for the CLS to find the most outstanding investment relationship managers and value guardians of listed companies in China’s capital market.  This selection is based on the following criteria such as company standard operation, quality level of information disclosure, investor relationship management level, market value management level, resource integration capability and leadership, combined with voting of investors and media reporters and opinions of the industry experts.  It took 3 months to select the winners with the most rigorous methodology.

Since Medicilon’s listing on November 5, 2019, Mr. Wang, as the spokesperson and internal coordination and management”, has relied on his own high requirements and excellent professional standards to continuously optimize information disclosure and investor relations, to actively promote the scientific decision-making and standardized operation of the board of directors, to continuously improve the R&D strength and branding, and to protect the Medicilon’s capital in stable path.

Mr. Guolin Wang won the “Elite Board Secretary Award” this time, following another 3 awards that Mr. Wang received previously, this fully reflects the high recognition of Mr. Wang and Medicilon in terms of information disclosure, investor relations and capital operation by regulatory agencies, industry experts and investors.

In the future, Medicilon will continue to implement the company’s development strategy plan with the concept of “innovation driven, quality first” as always, to actively innovate the investor relationship management model, to improve the quality of information disclosure, and to strive to create value for shareholders and investors.